High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment
- 11 March 2010
- journal article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 28 (5) , 578-584
Abstract
To evaluate the possible interaction of metabolic effects in the mevalonate pathway between amino-bisphosphonates (amino-BP) and vitamin K, the serum level of undercarboxylated osteocalcin (ucOC) was measured in amino-BP users in relationship to incident fracture occurrence. Osteoporotic patients (mean age, 70.7 ± 9.1 years; n = 231) treated with alendronate or risedronate were followed for 3.4 ± 2.1 years, and observations regarding the presence or absence of incident fractures in their vertebrae were made based on vertebral X-ray films every year. During the observation period, new fractures were found in a total of 71 patients (incident vertebral fracture, n = 61; the remaining 10 patients had long bone fractures). The baseline data of the patients with incident fractures indicated that incident fractures are more likely to occur in older patients who have a higher number of prevalent vertebral fractures and lower baseline lumbar bone mineral density (LBMD) as compared to patients without incident fractures. There was no significant difference in the changes of LBMD and urinary excretion of NTX after treatment. On the other hand, the serum level of ucOC in patients with incident fractures and with amino-BP treatment was significantly higher (2.75 ± 0.19 ng/ml) than that in patients without incident fractures and with amino-BP treatment (2.28 ± 0.13 ng/ml) (P = 0.038). These results indicate that older age, a greater number of prevalent fractures and higher ucOC levels, and lower LBMD are risks for incident fractures despite use of amino-BP. The time-dependent incident fracture rate was higher in accordance with an increase in the number of risk items (P < 0.001 in log-rank and Wilcoxon tests). In conclusion, measurement of undercarboxylated osteocalcin may be useful for assessing fracture risk in patients receiving amino-BP treatment.Keywords
This publication has 24 references indexed in Scilit:
- Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective studyJournal of Bone and Mineral Metabolism, 2009
- Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal womenJournal of Bone and Mineral Metabolism, 2008
- Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysisThe Lancet, 2007
- Vitamin K and the Prevention of FracturesArchives of internal medicine (1960), 2006
- The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research GroupJournal of Bone and Mineral Metabolism, 2006
- Vitamin K2 Regulation of Bone Homeostasis Is Mediated by the Steroid and Xenobiotic Receptor SXRJournal of Biological Chemistry, 2003
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With RisedronateJournal of Bone and Mineral Research, 2003
- Diagnostic criteria for primary osteoporosis: year 2000 revisionJournal of Bone and Mineral Metabolism, 2001
- Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosisJournal of Bone and Mineral Research, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995